World's Best Scientists 2026 revealed!
Richard F. Kefford

Richard F. Kefford

Award Badge
Medicine
Australia
2023

D-Index & Metrics

Medicine

D-Index
118
Citations
78170
World Ranking
3973
National Ranking
109

Research.com Recognitions

  • 2023 - Research.com Medicine in Australia Leader Award
  • 2016 - Fellow of the Australian Academy of Health and Medical Science

Overview

Richard F. Kefford is affiliated with Macquarie University in Australia and has contributed extensively to research in medicine, particularly in oncology and molecular biology. Their work spans several important subfields including immunology and public health, with a focus on cancer immunotherapy and biomarker research.

The scientist's research topics cover a range of areas in cancer treatment and diagnostics. Major themes include:

  • Cancer Immunotherapy and Biomarkers
  • Melanoma and MAPK Pathways
  • CAR-T Cell Therapy Research
  • Immunotherapy and Immune Responses
  • Cancer Genomics and Diagnostics
  • Cutaneous Melanoma Detection and Management
  • Clinical Practice Guidelines Implementation

Frequent publication venues for their work include:

  • Clinical Cancer Research
  • European Journal of Cancer
  • Cancers
  • Targeted Oncology
  • Internal Medicine Journal

Frequent coauthors who have collaborated with Richard F. Kefford are:

  • Georgina V. Long
  • Matteo S. Carlino
  • Alexander M. Menzies
  • Richard A. Scolyer
  • Helen Rizos

Among recent research papers, notable publications include:

  • Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition (2020, Nature Communications)
  • Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial (2020, The Lancet Oncology)
  • Clinicians' attitudes and perceived barriers and facilitators to cancer treatment clinical practice guideline adherence: a systematic review of qualitative and quantitative literature (2020, Implementation Science)
  • Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors (2020, Clinical Cancer Research)
  • Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials (2020, European Journal of Cancer)

Richard F. Kefford's work has been recognized by their election as a Fellow of the Australian Academy of Health and Medical Science in 2016.

Best Publications

  • Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Oncogenic Signaling Pathways in The Cancer Genome Atlas

    Francisco Sanchez-Vega;Marco Mina;Joshua Armenia;Walid K. Chatila

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Genomic Classification of Cutaneous Melanoma

    Rehan Akbani;Kadir C. Akdemir;B. Arman Aksoy;Monique Albert

  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

    Katherine A. Hoadley;Christina Yau;Christina Yau;Toshinori Hinoue;Denise M. Wolf

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Comprehensive Characterization of Cancer Driver Genes and Mutations.

    Matthew H Bailey;Collin Tokheim;Eduard Porta-Pardo;Sohini Sengupta

  • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

    Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi

  • Whole-genome landscapes of major melanoma subtypes

    Nicholas K. Hayward;Nicholas K. Hayward;James S. Wilmott;Nicola Waddell;Nicola Waddell;Peter A. Johansson

  • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

    G. V. Long;A. Hauschild;M. Santinami;V. Atkinson

  • Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

    Georgina V. Long;Alexander M. Menzies;Adnan M. Nagrial;Lauren E. Haydu

  • Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    Antoni Ribas;Omid Hamid;Adil Daud;F. Stephen Hodi

  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy

    Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao

  • Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

    Hubing Shi;Willy Hugo;Xiangju Kong;Aayoung Hong

  • Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

    Gerald S Falchook;Georgina V Long;Georgina V Long;Razelle Kurzrock;Kevin B Kim

  • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

    Georgina V. Long;Uwe Trefzer;Michael A. Davies;Richard F. Kefford

  • Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

    O. Hamid;C. Robert;C. Robert;A. Daud;F.S. Hodi

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.

    Hubing Shi;Gatien Moriceau;Xiangju Kong;Mi Kyung Lee

Frequent Co-Authors

Georgina V. Long
Georgina V. Long University of Sydney
Richard A. Scolyer
Richard A. Scolyer Royal Prince Alfred Hospital
Helen Rizos
Helen Rizos Macquarie University
Alexander M. Menzies
Alexander M. Menzies University of Sydney
Matteo S. Carlino
Matteo S. Carlino University of Sydney
Graham J. Mann
Graham J. Mann Australian National University
John F. Thompson
John F. Thompson University of Sydney
Caroline Robert
Caroline Robert University of Paris-Saclay
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Peter Hersey
Peter Hersey University of Sydney

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA extends far beyond the traditional MD route. Nursing pathways, in particular, offer a range of flexible online options that can accelerate your healthcare career. For those already holding an RN license, consider the best online rn to bsn programs without clinical requirements. These programs allow working nurses to advance their qualifications with minimal disruption and without additional in-person clinical hours.

Ambitious nurses looking to elevate their practice may be interested in more advanced degrees, such as the Doctor of Nursing Practice. If time is a priority, explore dnp online programs designed for fast completion. Some options are also recognized as the easiest dnp programs, focusing on streamlined coursework and supportive learning environments.

For those starting out or seeking an entry point into nursing, fast track lpn options provide a quicker pathway to becoming a Licensed Practical Nurse fully online. Whether advancing a current career or stepping into healthcare for the first time, these online programs offer flexible, accessible opportunities for anyone aspiring to work in medicine in the USA.

Best Scientists Citing Richard F. Kefford

Trending Scientists